TAGRISSO is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR ...

If you have a certain type of lung cancer, your doctor may prescribe Tagrisso. It’s used to treat specific kinds of non-small cell lung cancer in adults. For more details about Tagrisso’s uses, see ...

Tagrisso significantly improves overall survival in unresectable stage 3 EGFR-mutant NSCLC, surpassing placebo in the LAURA study. The FDA approved Tagrisso in September 2024 for patients with locally ...

Tagrisso (osimertinib) was granted a Breakthrough Therapy Designation for the firstline treatment of patients who have metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). Tagrisso ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a prespecified exploratory analysis of the positive ADAURA Phase III trial showed AstraZeneca’s TAGRISSO ® (osimertinib) demonstrated a clinically ...

WILMINGTON, Del., July 21, 2025--(BUSINESS WIRE)--Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO ® (osimertinib) ...

SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity Susan Galbraith, ...

Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO ® (osimertinib) with the addition of pemetrexed and platinum-based ...

How Well Does Tagrisso Work for Lung Cancer? The FDA approved Tagrisso based on clinical trials for EGFR-mutated lung cancer in several different scenarios. Tagrisso was studied in people who had lung ...

AstraZeneca AZN announced that the European Commission (EC) has approved its blockbuster lung cancer drug, Tagrisso (osimertinib) for expanded use in a lung cancer indication. The EC has now approved ...